Alkem Laboratories Ltd. · NSE:ALKEM

Alkem Laboratories — Q2 FY27 Earnings Presentation

21 slides from Alkem Laboratories's earnings presentation, Nov 12, 2026

  1. Slide 1: Exchange filing cover letter

    12th November, 2026 To, The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Press Release and

  2. Slide 2: Press Release: Alkem reports 14% revenue growth in Q2FY27

    Press Release Alkem reports 14% revenue growth in Q2FY27 Mumbai, November 12, 2026: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the second quarter ended September 30, 2026. The Board of Directors took record of these results at its meeting held in Mu

  3. Slide 3: Press release: domestic, international highlights and facility status

    o The Company registered a growth of 13.8% YoY a t p a r w i t h Indian Pharmaceutical Market (IPM), growth of 13.8%. o Acute segment reported growth of 12.1% at par with IPM growth of 12.3%. o Chronic segment reported growth of 22.4% vs. IPM which grew by 16%, +640 bps outperformance. o We have out

  4. Slide 4: About Alkem

    About Alkem: Alkem Laboratories Ltd. is the sixth - largest pharmaceutical company in the Indian market, with a legacy spanning over 50+ years of providing high-quality medicines to patients. It holds a dominant position in the therapy areas of anti-infectives, gastrointestinal disorders, pain manag

  5. Slide 5: Invite for Q2FY27 & H1FY27 Conference Call

    Invite for Q2FY27 & H1FY27 Conference Call at 4.30 pm IST, November 12, 2026 Mumbai, November 04, 2026: Alkem Laboratories Ltd. (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) will hold a conference call for investors and analysts on Thursday, November 12, 2026, from 4:30 pm to 5:30

  6. Slide 6: Q2 FY27 Results Presentation

    Alkem Laboratories Ltd. Q2 FY27 Results Presentation 12th November 2026 1

  7. Slide 7: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and

  8. Slide 8: ALKEM - Advancing Healthcare. Enriching Patient Lives.

    ALKEM - Advancing Healthcare. Enriching Patient Lives. Building healthcare solutions across pharmaceuticals, biosimilars and MedTech to improve access, enhance the treatment experience & deliver better patient outcomes India International Markets • #3 player in Acute Therapy1 • US - 170 ANDAs approv

  9. Slide 9: Q2FY27 Performance at Glance

    Q2FY27 Performance at Glance Key Financial Highlights Highlights of Q2FY27 45,520 mn Revenue ▪ Revenue from operations grew 13.8% YoY; gross margin1 expanded 220 bps YoY to 67.2%. 13.8% YoY ▪ India business grew 9.5%; as per IQVIA SSA, Alkem grew 13.8% at par with 10,252 mn EBITDA IPM growth of 13.8

  10. Slide 10: Key Financial Metrics

    Key Financial Metrics Total Revenue from Operations1 (INR mn) EBITDA (INR mn) & EBITDA Margins3 % 23.0% 22.2% 14.4% 20.5% 22.5% 50,000 45,520 12,000 10,252 45,000 40,010 9,208 40,000 37,369 36,033 37,402 10,000 8,280 35,000 8,000 7,661 30,000 25,000 6,000 5,174 20,000 4,000 15,000 10,000 2,000 5,000

  11. Slide 11: Domestic Business Performance – Focus on Outperforming Market

    Domestic Business Performance – Focus on Outperforming Market India3 sales grew 9.5% YoY Strengthening Patient Access Through New Launches Sales (In INR mn) ▪ Launched 26 products in H1FY27 Q2 FY27 Sales Contribution 35,000 ▪ Multiple launches across various therapy areas 30,275 30,000 27,660 24,610

  12. Slide 12: Strong momentum from our mega brands

    Strong momentum from our mega brands has been pivotal in building robust brand franchises and consistently scaling them over the years #2 ‘PAN’ 15 Brands 31 Brands Biggest Brand family in the Among the Top 3 ranks in their in the IPM Top 300 ranks IPM CVM1 (Brands > ₹250 Mn) Building large brand fam

  13. Slide 13: US Business Performance

    US Business Performance US Sales Performance1 Highlights for the Quarter ▪ Sales grew 2.4% YoY to INR 7,830 mn; growth was largely Sales (In INR mn) Q2 FY27 Sales Contribution led by volume growth 10,000 9,000 7,830 8,000 7,675 7,649 ▪ Mid teens price erosion due to additional competition in 7,000 6

  14. Slide 14: International Markets (Non-US) Business Performance

    International Markets (Non-US) Business Performance Strengthening International Markets1 through Occlutech Highlights for the Quarter ▪ Non-US sales grew 58% YoY to INR 6,710 mn, contributing 15% of Sales (In INR mn) Q2 FY27 Sales total sales (14% in Q2 FY26) Contribution 9,000 8,000 ▪ Growth was dr

  15. Slide 15: Biotech and MedTech

    Biotech and MedTech Building new growth engines Key Highlights MedTech ~₹ 704 mn ▪ Occlutech was integrated from Q2 FY27; Q2 FY27 sales include Q2 FY27 Biotech sales, #5th Indian Company with a mAB in Occlutech's contribution De-grew 35% YoY Europe Biosimilars Foot Print Across ▪ Commercialized prod

  16. Slide 16: Q2 FY27 – P&L Highlights

    Q2 FY27 – P&L Highlights % of % of YoY % of QoQ Particulars Q2’FY27 Q2’FY26 Q1’FY27 Revenue Revenue Growth Revenue Growth Total Revenue from 45,520 100.0% 40,010 100.0% 13.8% 37,402 100.0% 21.7% Operations Gross Profit (ex-Other 30,572 67.2% 26,000 65.0% 17.6% 25,389 67.9% 20.4% income) EBITDA 10,25

  17. Slide 17: H1 FY27 – P&L Highlights

    H1 FY27 – P&L Highlights Particulars H1’FY27 % of Revenue H1’FY26 % of Revenue YoY Growth Total Revenue from Operations 82,921 100.0% 73,721 100.0% 12.5% Gross Profit (ex-Other income) 55,961 67.5% 47,999 65.1% 16.6% EBITDA 17,912 21.6% 16,598 22.5% 7.9% PBT (before exceptional items) 17,366 20.9% 1

  18. Slide 18: Balanced Ownership Structure

    Balanced Ownership Structure Shareholding as of 30 September 2026 | % Equity Share capital MARKET SNAPSHOT NSE / BSE ALKEM / 539523 Promoter & Promoter Group 49.7% FIIs 10.3% Shares outstanding ~120 Mn Mutual Institutions 33.2% funds 19.7% Market capitalisation Rs 617.4 Bn Non-institutions 17.2% Ins

  19. Slide 19: Alkem Laboratories at a Glance

    Alkem Laboratories at a Glance FY26 India-led franchise combines market leadership, operating scale and healthy profitability 01 MARKET LEADERSHIP 02 SCALE 03 PROFITABILITY Relative position across key India metrics India remains the core of the operating platform Margin profile and returns Prescrip

  20. Slide 20: Key Awards & Recognition

    Key Awards & Recognition Recognition across corporate excellence, people, innovation, patient impact and brand leadership Corporate Excellence: Pharma Company of the Year at the Financial CSR: CSR Programme of the Year at the Financial Express Pharma Express Pharma Awards 2026. Awards 2026 for the B

  21. Slide 21: Thank You

    THANK YOU For any queries, contact: Stay updated on Smeett Jain Disclaimer: This is a confidential email from Alkem Laboratories Limited. The contents of this email and any attachments are solely intended for the addressee(s) and in all likelihood contain information that is legally privileged. If yo

Alkem Laboratories — Q2 FY27 Earnings Presentation on 6ix